← Back to 1B-LSD

1B-LSD Stats & Data

Psychedelic Research-chemical

1b 1-butyryl-lsd

NPS DataHub

MW393.53

FormulaC24H31N3O2

CAS2349376-12-9

IUPAC(6aR,9R)-4-butanoyl-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide

SMILESCCCC(=O)n1cc2CC3N(C)CC(C(=O)N(CC)CC)C=C3c3cccc1c23

InChIKeySVRFNPSJPIDUBC-DYESRHJHSA-N

2020/5.2 Δ9 10-Ergolene; 2021/5.2 Δ9 10-Ergolene; 2022/5.2 Δ9 10-Ergolene

Chemical Class Lysergamide

Psychoactive Class Psychedelic

Half-Life Human pharmacokinetics uncharacterised; LSD produced has plasma t1/2 ≈ 3–5 h.

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (partial)

Other

prodrug of LSD

History & Culture

1B-LSD emerged on the online research chemical market in August 2016, following a pattern common among novel lysergamide derivatives designed to occupy legal grey areas in jurisdictions where LSD itself is controlled. The identity of the original synthesizer remains unknown, and notably, no academic literature documenting the compound exists prior to its commercial appearance—suggesting it was developed specifically for the grey market rather than originating from traditional pharmaceutical or academic research. The strategic use of 1-alkylated lysergamide derivatives to circumvent controlled substance laws was anticipated well before 1B-LSD's emergence. A 1988 report from the United States Drug Enforcement Administration foresaw that modifications to the lysergamide core structure could be employed to create functional LSD analogues that technically fall outside existing scheduling frameworks, presaging the wave of designer lysergamides that would appear decades later.

Effect Profile

Curated + 2 Reports

Psychedelic 9.2

Strong visuals, headspace, and auditory effects with moderate body load

Visual Intensity×3

Headspace Depth×3

Auditory Effects×1

Body Load / Somatic Effects×1

Based on reports from:

Effect Index The Glory of the Sun — nervewing Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 1B-LSD

Duration Timeline

Bluelight

Onset Comeup Peak Offset After Effects

Oral

19 minutes - 1.0 hours

45 minutes - 2.0 hours

3-5 hours

6-24 hours

Total: 8-12 hours

Sublingual

19 minutes - 1.0 hours

45 minutes - 2.0 hours

3-5 hours

6-24 hours

Total: 8-12 hours

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Human pharmacokinetics uncharacterised; LSD produced has plasma t1/2 ≈ 3–5 h.

Addiction Potential

Very low. Animal studies fail to show self-administration; human use is limited by rapid tolerance and lack of reinforcing euphoria, analogous to LSD.

Tolerance Decay

Full tolerance 1d Half tolerance 5d Baseline ~14d

Rapid tolerance after a single session; meaningful reduction after ~5–7 days; near‑baseline by ~14 days is typical for LSD‑like psychedelics. Data are based on human experience and general psychedelic pharmacology rather than controlled trials.

Cross-Tolerances

LSD

90% ●●○

psilocybin/psilocin

70% ●●○

other serotonergic psychedelics

60% ●○○

Experience Report Analysis

Erowid

2 Reports

2019–2020 Date Range

2 With Age Data

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Real-World Dose Distribution

62K Doses

From 10 individual dose entries

Read full reports on Erowid →

Legal Status

Not scheduled under the UN Convention on Psychotropic Substances

Country	Status	Notes
Austria	Grey area (NPSG may apply)	While not technically illegal by name, 1B-LSD may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) as a structural analogue of LSD, rendering it illegal to supply for human consumption.
Germany	Controlled (NpSG)	Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production and import with intent to distribute, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to penalty.
Japan	Illegal	Controlled under the Pharmaceutical Affairs Law. Both possession and sale are prohibited.
Latvia	Illegal	Although not officially scheduled by name, 1B-LSD is controlled as a structural analogue of LSD pursuant to an amendment enacted on June 1, 2015.
Lithuania	Illegal	Specifically named on the national list of controlled substances since June 5, 2019.
Singapore	Illegal	Prohibited under Singapore's controlled substances legislation.
Sweden	Illegal	Prohibited as of January 26, 2016, following its emergence as a designer drug. Sweden's public health agency further recommended classifying it as a hazardous substance on June 24, 2019.
Switzerland	Controlled (with exceptions)	Considered a controlled substance as a defined derivative of lysergic acid under Verzeichnis E, point 263. Remains legal when used exclusively for scientific or industrial purposes.
United Kingdom	Illegal (Psychoactive Substances Act)	Prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016. Production, supply, and importation are criminal offenses.
United States	Unscheduled (Federal Analogue Act applies)	Not explicitly listed as a controlled substance. However, as a prodrug that metabolizes to LSD, possession and sale may be prosecutable under the Federal Analogue Act when intended for human consumption.

Harm Reduction

drugs.wiki

• Sublingual units corrected from “g” to “µg” to prevent misinterpretation; lysergamides are dosed in micrograms. TripSit and multiple HR sources list LSD-class dosing in µg, not mg or g.

• Blotter potency is highly variable and often over‑stated; Swiss drug‑checking found mean LSD content near ~76–81 µg per tab (2023–2024). Start with a partial tab if untested. Wait up to 3 hours before considering any redose because delayed-onset adulterants sometimes appear on blotter. Use professional drug checking when available; many services accept blotter pieces.

• Reagent testing: Ehrlich (p‑DMAB) turns violet with indole lysergamides (LSD, 1B‑LSD). NBOMe/NBOH phenethylamines do not give this reaction, so a negative Ehrlich is a red flag for non‑lysergamide blotters.

• Avoid lithium entirely with psychedelics; numerous case reports and user accounts describe seizures and severe adverse reactions when combined.

• Avoid tramadol and be cautious with other seizure‑threshold–lowering medicines (e.g., bupropion); combine only under medical oversight.

• Combining with potent stimulants (e.g., amphetamines, cocaine) increases tachycardia, blood pressure, anxiety, and risk of panic or manic states.

• Cannabis frequently potentiates visual and cognitive effects; it also increases the chance of anxiety and confusion during come‑up and peak.

• Set and setting matter: use in a safe, familiar environment with a trusted sober sitter if inexperienced. Postpone if feeling unwell or unstable.

• Storage: like LSD, 1B‑LSD on blotter is degraded by heat, light, oxygen, and moisture. Best practice is foil wrap, airtight container with desiccant, stored cold and dark (freezer).

• Tolerance rises rapidly after a single dose and can make redoses during the same or next day unpredictably weak while increasing side‑effects. Allow at least ~2 weeks to return to baseline.

• As an N‑acyl lysergamide, 1B‑LSD is widely considered a prodrug of LSD. Treat unknown or novel analogs with the same caution as LSD, assuming full psychedelic potency and duration.